Premium
P3‐032: Identification of Predictors of Disease Progression in an Amyloid‐Beta 42 (Aβ42)‐Positive, Prodromal Alzheimer’s Disease Cohort: Analysis of the Scarlet Road Study
Author(s) -
Sun Shuguang,
Model Fabian,
Nikolcheva Tania,
Lasser Robert A.
Publication year - 2016
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2016.06.1689
Subject(s) - hazard ratio , medicine , cohort , proportional hazards model , placebo , disease , clinical endpoint , biomarker , cohort study , clinical trial , confidence interval , pathology , biochemistry , chemistry , alternative medicine
Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, Netherlands; 2 University of Leicester, Leicester, United Kingdom; 3 Global Innovative Pharma Business – Clinical Sciences Pfizer, Paris, France; Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, Netherlands; 5 VU University Medical Center, Amsterdam, Netherlands. Contact e-mail: l.vermunt@vumc.nl